Description
Hemlibra 60mg Injection is a groundbreaking medication designed for the treatment of Hemophilia A. Its active ingredient, emicizumab, is a bispecific antibody that mimics the function of a missing clotting factor (Factor VIII) in individuals with Hemophilia A. By bridging activated Factor IX and Factor X, emicizumab facilitates the formation of the tenase complex, thereby promoting blood clot formation and reducing the frequency of bleeding episodes. This innovative approach offers a new therapeutic option for patients who previously relied on frequent factor infusions or bypass agents. Hemlibra is indicated for routine prophylaxis to prevent or reduce the frequency of bleeding in patients with Hemophilia A. The dosage and administration should be determined by a healthcare professional based on the individual patient’s needs. Common side effects may include injection site reactions, headache, and joint pain. It is crucial to store Hemlibra 60mg Injection as per the manufacturer’s instructions, typically refrigerated and protected from light. Always consult your doctor or pharmacist for personalized medical advice and before making any changes to your treatment regimen.
